SCHEMBL6285927

SCHEMBL6285927

COc1ccc(-c2cc3ccncc3[nH]2)cc1NC(=S)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.52
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 9/20 0.47
MAPT P10636 5/20 0.47
MEN1 O00255 5/20 0.47
LMNA P02545 4/20 0.47
HPGD P15428 2/20 0.47
PKM P14618 2/20 0.42
GAA P10253 5/20 0.41
SMN1; SMN2 Q16637 2/20 0.39
NSD2 O96028 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
BLM P54132 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
SMO Q99835 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286947 0.93 KMT2A (0.52) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6286353 0.89 ALDH1A1 (0.50) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6496744 0.86 KMT2A (0.51) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6288130 0.84 KMT2A (0.47) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6286023 0.84 ALDH1A1 (0.57) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6279218 0.84 RIPK1 (0.55) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6288146 0.84 ALDH1A1 (0.48) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6288185 0.83 KMT2A (0.47) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6504811 0.83 KMT2A (0.49) KMT2AKDM4EALDH1A1MAPTMEN1
SCHEMBL6286002 0.82 KMT2A (0.50) KMT2AKDM4EALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US claimed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B KMT2A 4200/4885KDM4E 2221/4885ALDH1A1 522/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.